Innate Pharma (IPHA) Short Interest Ratio & Short Volume $2.08 -0.02 (-0.90%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Innate Pharma Short Interest DataInnate Pharma (IPHA) has a short interest of 70,200 shares, representing 0.11% of the float (the number of shares available for trading by the public). This marks a 35.00% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.8, indicating that it would take 4.8 days of the average trading volume of 7,604 shares to cover all short positions.Current Short Interest70,200 sharesPrevious Short Interest52,000 sharesChange Vs. Previous Month+35.00%Dollar Volume Sold Short$148.12 thousandShort Interest Ratio4.8 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares92,180,000 sharesShort Percent of Float0.11%Today's Trading Volume3,328 sharesAverage Trading Volume7,604 sharesToday's Volume Vs. Average44% Short Selling Innate Pharma? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHA Short Interest Over TimeIPHA Days to Cover Over TimeIPHA Percentage of Float Shorted Over Time Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202570,200 shares $148.12 thousand +35.0%0.1%4.8 $2.11 7/15/202552,000 shares $92.04 thousand -14.3%N/A2.9 $1.77 6/30/202560,700 shares $110.17 thousand +17.9%0.1%3.1 $1.82 6/15/202551,500 shares $97.59 thousand -8.4%0.1%2.1 $1.90 5/31/202556,200 shares $121.39 thousand -14.5%0.1%2.4 $2.16 5/15/202565,700 shares $138.63 thousand -82.5%0.1%1.9 $2.11 4/30/2025376,100 shares $838.70 thousand -2.6%N/A1.7 $2.23 4/15/2025386,100 shares $737.45 thousand -5.2%0.7%1.7 $1.91 3/31/2025407,300 shares $724.99 thousand -2.4%0.7%1.8 $1.78 3/15/2025417,100 shares $812.93 thousand -9.6%0.7%1.8 $1.95 Get the Latest News and Ratings for IPHA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025461,400 shares $978.17 thousand +199.2%0.8%0.7 $2.12 2/15/2025154,200 shares $299.15 thousand +1.1%0.3%0.2 $1.94 1/31/2025152,500 shares $279.08 thousand +44.7%N/A0.3 $1.83 1/15/2025105,400 shares $179.18 thousand +4.4%N/A0.2 $1.70 12/31/2024101,000 shares $185.84 thousand -88.9%N/A0.2 $1.84 12/15/2024909,800 shares $2.75 million +1,344.1%N/A2 $3.02 11/30/202463,000 shares $97.02 thousand -1.1%N/A0.3 $1.54 11/15/202463,700 shares $91.73 thousand -2.3%N/A6.2 $1.44 10/31/202465,200 shares $123.29 thousand +10.9%N/A7.8 $1.89 10/15/202458,800 shares $119.36 thousand -18.1%N/A7.4 $2.03 9/30/202471,800 shares $164.42 thousand +20.3%N/A10 $2.29 9/15/202459,700 shares $134.92 thousand -8.3%N/A9 $2.26 8/31/202465,100 shares $149.40 thousand -2.5%N/A9.3 $2.30 8/15/202466,800 shares $150.30 thousand +3.6%N/A8.1 $2.25 7/31/202464,500 shares $138.35 thousand -11.5%N/A7.8 $2.15 7/15/202472,900 shares $154.55 thousand +5.2%N/A9.1 $2.12 6/30/202469,300 shares $134.44 thousand -4.9%N/A7.7 $1.94 6/15/202472,900 shares $171.32 thousand +4.1%N/A7 $2.35 5/31/202470,000 shares $191.80 thousand -0.3%N/A6.7 $2.74 5/15/202470,200 shares $175.94 thousand -11.3%N/A7.2 $2.51 4/30/202479,100 shares $182.72 thousand -2.7%N/A8.8 $2.31 4/15/202481,300 shares $196.75 thousand +5.7%N/A7.8 $2.42 3/31/202476,900 shares $221.47 thousand -13.7%N/A7.7 $2.88 3/15/202489,100 shares $217.40 thousand +13.7%N/A7.6 $2.44 2/29/202478,400 shares $205.41 thousand -4.9%N/A4.1 $2.62 2/15/202482,400 shares $212.59 thousand +8.4%N/A4.7 $2.58 1/31/202476,000 shares $203.68 thousand -0.9%N/A4 $2.68 1/15/202476,700 shares $214.76 thousand -8.9%N/A3.7 $2.80 12/31/202384,200 shares $235.76 thousand +55.9%N/A3.9 $2.80 12/15/202354,000 shares $130.14 thousand -5.9%N/A2.6 $2.41Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 11/30/202357,400 shares $137.76 thousand -4.3%N/A4.3 $2.40 11/15/202360,000 shares $147.60 thousand -6.0%N/A4.2 $2.46 10/31/202363,800 shares $151.84 thousand +11.5%N/A4.4 $2.38 10/15/202357,200 shares $132.42 thousand -8.5%N/A5 $2.32 9/30/202362,500 shares $158.13 thousand -3.4%N/A6 $2.53 9/15/202364,700 shares $192.16 thousand -1.5%N/A6.7 $2.97 8/31/202365,700 shares $191.32 thousand -8.1%N/A5.2 $2.91 8/15/202371,500 shares $206.64 thousand -3.8%N/A6.1 $2.89 7/31/202374,300 shares $218.44 thousand -1.9%N/A6.8 $2.94 7/15/202375,700 shares $244.51 thousand -3.8%N/A6.4 $3.23 6/30/202378,700 shares $242.00 thousand +20.0%N/A6.1 $3.08 6/15/202365,600 shares $213.86 thousand +9.7%N/A4 $3.26 5/31/202359,800 shares $175.81 thousand -4.3%N/A3.8 $2.94 5/15/202362,500 shares $186.88 thousand No ChangeN/A3.6 $2.99 10/31/2022147,600 shares $317.34 thousand +12.8%N/A12.9 $2.15 10/15/2022130,900 shares $261.80 thousand +15.5%N/A12.5 $2.00 9/30/2022113,300 shares $226.60 thousand +1.3%N/A12.7 $2.00 9/15/2022111,900 shares $284.23 thousand +2.3%N/A13.3 $2.54 8/31/2022109,400 shares $293.19 thousand +0.2%N/A6.4 $2.68 8/15/2022109,200 shares $321.05 thousand -10.1%N/A5.9 $2.94 7/31/2022121,500 shares $388.79 thousand -3.6%N/A6.1 $3.20 7/15/2022126,000 shares $347.76 thousand +0.3%N/A4.9 $2.76 6/30/2022125,600 shares $339.12 thousand +3.9%N/A4.8 $2.70 6/15/2022120,900 shares $305.88 thousand +1.9%N/A4.6 $2.53 5/31/2022118,700 shares $315.74 thousand -13.6%N/A6.2 $2.66 5/15/2022137,300 shares $394.05 thousand +8.0%N/A6.7 $2.87 4/30/2022127,100 shares $364.78 thousand -9.3%N/A5.7 $2.87 4/15/2022140,100 shares $438.51 thousand +4.0%N/A6 $3.13 3/31/2022134,700 shares $452.59 thousand +105.0%N/A5.3 $3.36 3/15/202265,700 shares $207.61 thousand +13.9%N/A1.6 $3.16 2/28/202257,700 shares $196.76 thousand -2.5%N/A1 $3.41 2/15/202259,200 shares $219.63 thousand -15.6%N/A0.9 $3.71 1/31/202270,100 shares $265.68 thousand -15.3%N/A1 $3.79 1/15/202282,800 shares $375.08 thousand -22.3%N/A1.1 $4.53 12/31/2021106,600 shares $486.10 thousand +247.2%N/A1.3 $4.56 12/15/202130,700 shares $158.11 thousand +0.3%N/A0.3 $5.15 11/30/202130,600 shares $151.78 thousand -39.8%N/A0 $4.96 11/15/202150,800 shares $263.65 thousand +195.4%N/A0 $5.19 10/29/202117,200 shares $99.76 thousand +18.6%N/A0 $5.80 10/15/202114,500 shares $85.12 thousand -89.5%N/A0 $5.87 9/30/2021137,800 shares $850.23 thousand +79.7%N/A0.1 $6.17 9/15/202176,700 shares $427.99 thousand +2,456.7%N/A0 $5.58 8/31/20213,000 shares $10.92 thousand -45.5%N/A0 $3.64 8/13/20215,500 shares $18.70 thousand -35.3%N/A0.3 $3.40 7/30/20218,500 shares $28.22 thousand -33.6%N/A0.5 $3.32 7/15/202112,800 shares $41.47 thousand +100.0%N/A0.7 $3.24 6/30/20216,400 shares $21.06 thousand -61.0%N/A0.4 $3.29 6/15/202116,400 shares $65.76 thousand +1,161.5%N/A1.1 $4.01 5/28/20211,300 shares $5.08 thousand +225.0%N/A0.1 $3.91 5/14/2021400 shares $1.58 thousand -81.8%N/A0 $3.95Elon’s BIGGEST warning yet? (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.Click here to see why Tesla's about to prove everyone wrong... again. 4/30/20212,200 shares $9.42 thousand -29.0%N/A0.1 $4.28 4/15/20213,100 shares $13.58 thousand -55.7%N/A0 $4.38 3/31/20217,000 shares $30.03 thousand -6.7%N/A0.2 $4.29 3/15/20217,500 shares $34.28 thousand +53.1%N/A0.2 $4.57 2/26/20214,900 shares $21.66 thousand -27.9%N/A0.1 $4.42 2/12/20216,800 shares $30.80 thousand +385.7%N/A0.2 $4.53 1/29/20211,400 shares $5.74 thousand -74.1%N/A0 $4.10 1/15/20215,400 shares $24.52 thousand -77.2%N/A0.2 $4.54 12/31/202023,700 shares $102.15 thousand -52.5%N/A0.9 $4.31 12/15/202049,900 shares $219.06 thousand +91.2%N/A2.5 $4.39 11/30/202026,100 shares $145.12 thousand -7.1%N/A1.5 $5.56 11/15/202028,100 shares $133.48 thousand -23.2%N/A1.6 $4.75 10/30/202036,600 shares $146.22 thousand +21.6%N/A2.5 $4.00 10/15/202030,100 shares $121.00 thousand +32.6%N/A2.5 $4.02 9/30/202022,700 shares $87.17 thousand -22.5%N/A2.2 $3.84 9/15/202029,300 shares $127.46 thousand +70.4%N/A2.9 $4.35 8/31/202017,200 shares $106.81 thousand -5.5%N/A2.2 $6.21 IPHA Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been closed out or covered. As of July 31st, traders have sold 70,200 shares of IPHA short. 0.11% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest. What is a good short interest ratio for Innate Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 5.0. Learn More on Innate Pharma's short interest ratio. What is a good short interest percentage for Innate Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.11% of Innate Pharma's floating shares are currently sold short. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a increase in short interest in July. As of July 31st, there was short interest totaling 70,200 shares, an increase of 35.0% from the previous total of 52,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? 0.11% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Innate Pharma: Niagen Bioscience, Inc. (4.29%), Pharming Group N.V. Sponsored ADR (0.01%), ArriVent BioPharma, Inc. (29.25%), Sana Biotechnology, Inc. (24.42%), Gyre Therapeutics, Inc. (11.38%), Oculis Holding AG (0.03%), Ginkgo Bioworks Holdings, Inc. (20.67%), atai Life Sciences N.V. (11.56%), Immatics N.V. (3.16%), Tango Therapeutics, Inc. (37.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies Niagen Bioscience Short Interest Pharming Group Short Interest ArriVent BioPharma Short Interest Sana Biotechnology Short Interest Gyre Therapeutics Short Interest Oculis Short Interest Ginkgo Bioworks Short Interest atai Life Sciences Short Interest Immatics Short Interest Tango Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IPHA) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access